Client issue
CRA Life Science experts were retained by a client to provide support on the impact of the EU Health Technology Assessment (HTA) regulation and the associated Joint Clinical Assessments (JCAs) on national HTA systems across Europe. Specifically, support was needed to understand policy implications, market access challenges, and related advocacy needs. Progress in national adaptation of the HTA procedures to incorporate JCAs was heterogeneous across European countries. The client needed to understand the variety of situations and formulate a common perspective, while accounting for individual country needs.
CRA approach
• We developed hypotheses based on experience regarding national-level policy access challenges posed by JCAs.
• Our team analysed policy developments and trends relating to the national implications of JCAs and potential scenarios, while identifying evidence gaps.
• We identified key information to ascertain cross-country issues, potential archetypes, and individual country specificities.
• Conducted a series of workshops with national representatives from over 20 European countries to validate our hypotheses, collect insights, and determine prevailing HTA needs.
Client impact
• The CRA team successfully disseminated the findings across the client’s various regional functions and local teams to establish a shared understanding of the issues.
• Determined key priorities and established policy recommendations and asks.
• Established a clearly defined course of action that incorporated both regional and national plans and objectives.
